[{"id":"d2dc3eeb-f2ce-453f-8773-580b0385f326","acronym":"NET-PACS","url":"https://clinicaltrials.gov/study/NCT04713202","created_at":"2021-02-11T16:55:42.533Z","updated_at":"2024-07-02T16:35:55.881Z","phase":"Phase 2","brief_title":"Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl","source_id_and_acronym":"NCT04713202 - NET-PACS","lead_sponsor":"Chandrikha Chandrasekhara","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xermelo (telotristat etiprate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-02-10"}]